Eric Campeau

Eric Campeau

Company: Zenith Epigenetics

Job title: Senior Director of Translational Medicine


Advance the Development of an Epigenetic-based Therapy in Castration-Resistant Prostate Cancer (CRPC) 9:30 am

• Explore the combination of the BET bromodomain inhibitor ZEN-3694 with enzalutamide: updated results from the Phase 2a trial • Discover mechanisms of resistance to enzalutamide targeted by ZEN-3694 • Examine translational data informing patient pre-selection strategyRead more

day: Day Two

Panel Discussion: Overview of Emerging Therapeutic Targets 9:30 am

• Examine the current treatment options and emerging targeted therapies: What approaches do we currently have? What are their limitations? • Discuss what is the role of the tumor micro-environment in mCRPC • Evaluate how the combination of several targeted therapies can be of benefit to patients with prostate cancer, when these therapies show limited…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.